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Abstract
Background
Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease character-
ized by cellular infiltration into the joints, hyperproliferation of synovial cells and bone dam-
age. Available treatments for RA only induce remission in around 30% of the patients, have
important adverse effects and its use is limited by their high cost. Therefore, compounds
that can control arthritis, with an acceptable safety profile and low production costs are still
an unmet need. We have shown, in vitro, that celastrol inhibits both IL-1β and TNF, which
play an important role in RA, and, in vivo, that celastrol has significant anti-inflammatory
properties. Our main goal in this work was to test the effect of celastrol in the number of sub-
lining CD68 macrophages (a biomarker of therapeutic response for novel RA treatments)
and on the overall synovial tissue cellularity and joint structure in the adjuvant-induced rat
model of arthritis (AIA).
Methods
Celastrol was administered to AIA rats both in the early (4 days after disease induction) and
late (11 days after disease induction) phases of arthritis development. The inflammatory
score, ankle perimeter and body weight were evaluated during treatment period. Rats were
sacrificed after 22 days of disease progression and blood, internal organs and paw samples
were collected for toxicological blood parameters and serum proinflammatory cytokine
quantification, as well as histopathological and immunohistochemical evaluation,
respectively.
Results
Here we report that celastrol significantly decreases the number of sublining CD68 macro-
phages and the overall synovial inflammatory cellularity, and halted joint destruction without
side effects.
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Conclusions
Our results validate celastrol as a promising compound for the treatment of arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic immune mediated inflammatory disease that is mainly
characterized by hyperproliferation of synovial cells, infiltration of mononuclear cells into the
synovium and early destruction of articular cartilage and bone, causing progressive damage to
the musculoskeletal system and consequently the loss of physical function and life quality [1–
3]. The most debilitating feature of RA is joint destruction, which is derived from an uncon-
trolled inflammatory process. RA joint synovial cellular infiltrate consists of activated macro-
phages, B and T cells, which secrete proinflammatory cytokines and other mediators of
inflammation [1, 4, 5] that not only perpetuate the inflammatory process but also increase
bone resorption [6–10]. In addition, activated synovial fibroblasts, chondrocytes and osteo-
clasts contribute to the underlying cartilage and bone damage [11]. Despite this clear link
between inflammation and increased bone turnover in RA and the existence of several thera-
peutical options, their efficacy on inflammation and bone treatment seem to be uncoupled,
with some drugs suppressing inflammation but failing to protect bone [12, 13] and others halt-
ing bone destruction but with no effect on controlling inflammation [14]. Moreover, drugs
used to treat RA, ranging from nonsteroidal anti-inflammatory drugs (NSAIDs) to disease-
modifying antirheumatic drugs (DMARDs), and biological DMARDs, still cause severe side
effects [15, 16] and are only able to induce remission in around 20–30% of the patients, leaving
the majority of the individuals affected by RA with a chronic inflammatory process that will
lead to damage. In addition to this, the most recent and innovative treatments are highly
expensive, representing a burden to national health services and creating a barrier to its use in
less effluent areas of the world. Therefore, compounds that can control arthritis, with an
acceptable safety profile and low production cost are still an unmet need.
In this context, we have recently identified celastrol, a pentacyclic triterpenoid compound
isolated from the roots of the Chinese herb Tripterygium wilfordii Hook F, as a potential RA
therapeutic candidate [17]. We have shown that celastrol inhibits both interleukin (IL)-1β and
tumour necrosis factor (TNF), which play an important role since the early phase of RA [18],
and has significant anti-inflammatory and anti-proliferative properties in an adjuvant-induced
rat model of arthritis (AIA) [17]. Supporting our own results, other studies using celastrol have
reported beneficial effects in various models of inflammation, diminishing joint swelling and
damage, serum IgG level, TNF and IL-1βmRNA and preventing disease progression [19].
Importantly, recent studies have also demonstrated that celastrol protects human chondrocytes
by down-regulating the expression of metalloproteinases (MMPs) and inducible nitric oxide
synthase (iNOS), suppresses several chemokines that mediate cellular joint infiltration [20],
impairs B cell development [21] and also regulates bone remodelling-related immune media-
tors and proinflammatory cytokines in AIA synovium-infiltrating cells cultured ex vivo and in
the RAW264.7 macrophagic cell line [22]. Celastrol might thus constitute an attractive candi-
date to have an early effect not only in controlling inflammation but also in preventing bone
structural disturbances that occur in arthritis.
The efficacy of new compounds in the treatment of RA has been associated with a decrease
in CD68 positive macrophages in the synovial sublining layer. This effect has been clearly dem-
onstrated for most of the effective treatments for RA, including classic treatments, such as
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prednisolone [23], gold salts [24], methotrexate [25, 26] and leflunomide [27], and also for bio-
logics such as infliximab [28, 29], anakinra [30, 31] and rituximab [32]. Interestingly, a study of
a CCL-2/MCP-1 monoclonal antibody antagonist demonstrated no change in CD68 sublining
macrophages and this was associated with no change in disease activity [33]. In accordance, a
C5aR antagonist did not affect CD68 sublining macrophages and no clinical effect occurred
[34]. Furthermore, a multicenter study on the correlation of the number of sublining CD68
cells and the change in DAS28 demonstrated excellent inter-centre agreement [32] and it has
been shown that the number of CD68 macrophages decreases with a reduction in disease activ-
ity as measured by Disease Activity Score [35]. Due to these very solid evidences, the number
of CD68 sublining macrophages has been proposed as a biomarker of therapeutic response to
be used in the test of novel treatments for RA [32]. Of interest, in the preclinical test of new
compounds, a number of observations have shown that effective RA treatments such as tofaci-
tinib [36] and methotrexate [37] also decrease CD68 sublining macrophages in animal models
of arthritis. Several experimental compounds have also shown an association between control
of arthritis and reduction in the number of CD68 macrophages in animal models of arthritis
[38–40].
Our aim in the herein study was to test the effect of celastrol treatment in the number of
sublining CD68 macrophages and on the overall synovial tissue cellularity and joint structure
in an animal model of arthritis, as a further argument to its possible efficacy in RA treatment.
In this work we report that celastrol significantly decreases the number of sublining CD68
macrophages and the overall synovial inflammatory cellularity, and halted joint destruction
without any detectable side effects.
Materials and Methods
Animal experimental design
Eight-week-old female wistar AIA rats were purchased from Charles River Laboratories Inter-
national (Massachusetts, USA). AIA rats were maintained under specific pathogen free (SPF)
conditions and housed per groups under standard laboratory conditions (at 22°C under
12-hour light/12-hour dark conditions). Humane end-points were established and animals
were sacrificed when presenting the maximum inflammatory score in more than 2 paws or
when presenting more than 20% of body weight loss. All experiments were approved by the
Animal User and Ethical Committees at the Instituto de Medicina Molecular (Lisbon Univer-
sity), according to the Portuguese law and the European recommendations. The dose of celas-
trol (1μg/g body weight daily) used in this study was based on that used in our previous study
[17] and in other studies [22]. The need for daily administrations is also supported by Zhang J.
et al who showed that the half-life of pure celastrol is approximately 10 hours [41]. Celastrol
(Sigma, Missouri, USA) stock solution of 100mg/ml in DMSO was dissolved in normal saline
solution and injected intraperitoneally in AIA rats after 4 days (early treatment group) and
after 11 days (late treatment group) of disease induction, when arthritis was already present. A
group of healthy non-arthritic and arthritic untreated female age-matched wistar rats sacrificed
at day 4 (baseline for the celastrol early-treated group, at preclinical stage, N = 13), day 11
(baseline for the celastrol late-treated group, at acute clinical stage, N = 18) and day 22 after
disease induction (chronic clinical stage) were used as controls in all experiments for compari-
son. At the preclinical AIA progression stage evidence of inflammation or bone erosion is still
lacking in the contralateral hind paw and fore paws. Hind paw swelling, inflammation and
joint erosions are steadily progressing during acute clinical stage and reach a plateau in the
chronic stage [42]. The inflammatory score, ankle perimeter and body weight were measured
during the period of treatment. Inflammatory score was evaluated by counting the score of
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each paw joint in a scale of 0–3 (0—absence; 1—erythema; 2—erythema and swelling; 3—
deformities and functional impairment). The total score of each animal was defined as the sum
of the partial scores of each affected joint [17, 43]. Rats were sacrificed by CO2 narcosis and
blood, internal organs as well as paw samples were collected.
Toxicological evaluation
For histopathological observation, lung, liver, kidney and spleen samples were collected at the
time of sacrifice. Samples were fixed immediately in 10% neutral buffered formalin solution
and then dehydrated with increasing ethanol concentrations (70%, 96% and 100%). Samples
were next embedded in paraffin, sectioned using a microtome, mounted on microscope slides
and stained with hematoxylin and eosin. Tissue histopathological changes were examined by a
pathologist blinded to the experimental groups. All images were acquired using a Leica DM
2500 microscope equipped with a color camera Leica MC170 HD (Leica microsystems, Wet-
zlar, Germany). Moreover, blood toxicological parameters, such as creatine kinase, urea, lactate
dehydrogenase and alanine transaminase, were measured in serum samples by enzyme linked
immunosorbent assay (ELISA) technique according to the manufacturer’s instructions (BioAs-
say Systems, California, USA). Samples were analyzed using a plate reader Infinite M200
(Tecan, Mannedorf, Switzerland).
Systemic cytokine quantification
Proinflammatory cytokines IL-1β (Boster Bio, California, USA), IL-6 (Boster Bio, California,
USA), IL-17 (Sunred Biological Technology, Shanghai, China) and TNF (RayBiotech, Georgia,
USA) were quantified in serum samples using specific rat ELISA kits according to the provi-
der's recommendations. Standard curves for each cytokine were generated by using reference
cytokine concentrations supplied by the manufacturer. Samples were analyzed using a plate
reader Infinite M200 (Tecan, Mannedorf, Switzerland).
Histological and immunohistochemical evaluation of hind paws
Left hind paw samples collected at the time of sacrifice were fixed immediately in 10% neutral
buffered formalin solution and then decalcified in 10% formic acid. Samples were next dehy-
drated and embedded in paraffin, serially sectioned at a thickness of 5 μm using a microtome,
mounted on microscope slides and stained with hematoxylin and eosin for morphological
examination of structural changes and cellular infiltration. Histopathological evaluation of rat
joints was performed in a blind fashion using 4 semi-quantitative scores: Sublining layer infil-
tration score (0—none to diffuse infiltration; 1—lymphoid cell aggregate; 2—lymphoid folli-
cles; 3—lymphoid follicles with germinal center formation); Lining layer cell number score
(0—fewer than three layers; 1—three to four layers; 2—five to six layers; 3—more than six lay-
ers); Bone erosion score (0—no erosions; 1—minimal; 2—mild; 3—moderate; 4—marked);
Global severity score (0—no signs of inflammation; 1—mild; 2—moderate; 3—severe) [17, 44,
45]. Paw sections were also used for immunohistochemical staining with CD68 (Abcam, Cam-
bridge, UK), CD163 (Biorbyt, Massachusetts, USA), CD3 (Abcam, Cambridge, UK), CD19
(Biorbyt, Massachusetts, USA) and Ki67 (Abcam, Cambridge, UK) antibodies. Tissue sections
were incubated with the primary antibody and with EnVision+ (Dako, Glostrup, Denmark).
Color was developed in solution containing diaminobenzadine-tetrahydrochloride (Sigma,
Missouri, USA), 0.5% H2O2 in phosphate-buffered saline buffer (pH 7.6). Slides were counter-
stained with hematoxylin and mounted. Immunohistochemical evaluation of rat joints was
performed in a blind fashion using a semi-quantitative score of 0–4 (0—no staining; 1–0–25%
staining; 2–25–50% staining; 3–50–75% staining; 4—more than 75% staining) [17]. Images
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were acquired using a Leica DM2500 (Leica Microsystems, Wetzlar, Germany) microscope
equipped with a color camera.
For a quantitative analysis of the immunohistochemical staining, we acquired whole-slide
color images of single tissue slides using a NanoZoomer SQ slide scanner (Hamamatsu Pho-
tonics, Hamamatsu City, Japan) with 20x magnification (0.46 μm resolution). We developed
an image analysis software written in MATLAB (Mathworks, Natick, MA) to identify and
count the number of positive cells that displayed a specific cytoplasmic staining in representa-
tive sections. Briefly, single cell nuclei stained with hematoxylin were identified by color thresh-
olding in the Lab color space with the range of parameters L = [40,72], a = [–11,20] and
b = [–37,12] followed by particle analysis. Dilated regions of interest (ROIs) with a radius of 5
pixels were next defined for each detected particle as the cytoplasmic area. The antibody stain-
ing was also identified by color thresholding in the Lab color space with the range of param-
eters L = [40,80], a = [–6,20] and b = [-0.2,33]. Each cell ROI was then evaluated for
antibody positive staining, defined by the occurrence of at least 20 pixels with a color value
included in the cytoplasmic Lab threshold range. We cropped areas of interest from whole-
slide color images corresponding to synovial membranes and the software was set to batch pro-
cess all images and output the total number of cells and the number of cells with positive anti-
body staining for each section. Then the density of positive cells was calculated by dividing the
positive cell count by the area value.
Statistical analysis
Statistical differences were determined with non-parametric Kruskal-Wallis (Dunn´s Multiple
Comparison tests) and Mann–Whitney tests using GraphPad Prism (GraphPad, California,
USA). Correlation analysis was performed with the Spearman test. Differences were considered
statistically significant for p<0.05.
Results
Celastrol safely suppresses inflammatory manifestations in rat adjuvant-
induced arthritis
To further validate the in vivo anti-inflammatory effect of celastrol in the context of arthritis,
we have used the AIA rat model. The AIA experimental arthritis shares some characteristics of
RA, such as hyperplasia of the synovial membrane, inflammatory infiltration of the joints,
deposition of immune complexes in articular cartilage, pannus formation and destruction of
bone. This model is also useful to characterize treatment responses by the reduction of inflam-
mation or changes in the synovial tissue [46]. Overall, the AIA model has been extensively
used to clarify the mechanisms of human RA pathogenesis and to identify potential targets and
new drugs for therapeutic intervention [47], and has thus been our model of choice for our
first experimental use of celastrol [17, 48].
Celastrol was intraperitoneally administrated at a dose of 1μg/g/daily after 4 days of disease
induction (early treatment group) and after 11 days of disease induction (late treatment group)
[17]. The inflammatory score and ankle perimeter were evaluated during the treatment period
(Fig 1 and S1 Fig). As shown in Fig 1A, all animals already presented signs of arthritis by the
fourth day of disease induction and after 9 days the untreated arthritic group started to increase
the inflammatory manifestations sharply. In contrast, in early celastrol-treated rats there was
minimal inflammatory activity or even complete abrogation of arthritis manifestations. In the
late treatment group, drug administration was started when animals already presented a mean
inflammatory score of 4, but celastrol still caused a significant decrease of arthritis manifestations
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over time. In fact, the only remaining sign of swelling was observed in most animals in the local
of injection of the adjuvant, for disease induction. This result shows that this drug has a signifi-
cant anti-inflammatory effect even when administrated at a later phase of arthritis development.
Celastrol showed a significant anti-inflammatory effect, as assessed by the evaluation of the
inflammatory score (p<0.0001 in early and late treatment groups vs. arthritic animals, shown in
Fig 1B) and also by the measurement of ankle perimeter (p<0.0001 in early and late treatment
groups vs. arthritic animals, shown in Fig 1C). Of note, by the end of the treatment, at day 22,
there were no significant differences between the celastrol early and late treatment groups.
Importantly, both treated groups showed a significant reduction in the inflammatory score when
compared with their baselines (p = 0.0002 in celastrol early-treated vs. arthritic rats sacrificed at
day 4 and p<0.0001 in celastrol-late treated vs. arthritic rats sacrificed at day 11).
Up to now significant adverse effects of celastrol administration have not been reported.
However the few toxicological analysis of this compound in vivo were based in data from the
assessment of animal mortality and some blood parameters in studies using Tripterygium wil-
fordii plant extracts [49]. To investigate the potential side effects of pure celastrol
Fig 1. (A) Celastrol ameliorates inflammation throughout time. Notice that after 7 days of treatment
celastrol early-treated rats presented minimal inflammatory activity, whereas arthritic rats started to
increase the inflammatory manifestations sharply. Arrows indicate the beginning of treatment after 4
and 11 days of disease induction. (B) Celastrol improves the clinical outcome in adjuvant-induced
arthritic rats. Inflammatory score in celastrol-treated AIA rats is maintained significantly diminished
in comparison with arthritic rats. (C) Celastrol suppresses the progression of swelling in the left hind
paw. Left paw edema/swelling is markedly present in arthritic rats in contrast to celastrol-treated animals.
Data are expressed as median with interquartile range. Differences were considered statistically significant
for p-values<0.05, according to the Kruskal-Wallis (Dunn´s Multiple Comparison tests) and Mann–Whitney
tests. Healthy N = 19, Arthritic N = 23, Celastrol early group N = 15 and Celastrol late group N = 15.
doi:10.1371/journal.pone.0142448.g001
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administration in AIA rats, we performed liver and renal function tests, such as the measure-
ment of creatine kinase, urea, lactate dehydrogenase and alanine transaminase in serum sam-
ples collected at the time of sacrifice. No significant differences were observed in these
parameters when comparing arthritic rats with animals under treatment (p = 0.2). In addition,
a pathologist blinded to experimental groups examined the tissue histological sections and has
reported no evidence of drug-induced liver or renal injury, as well as no lung or spleen alter-
ations (S2 Fig). Of note, body weight variations were recorded throughout treatment duration,
and no weight loss was observed due to celastrol administration (p = 0.1265 and p = 0.6005 in
celastrol early and late treatment groups vs. arthritic rats, respectively). Contrarily, there was
an association between disease activity and weigh loss (p = 0.0273 in arthritic rats vs. healthy
animals). In fact, in the late treatment group, animals started to lose weight due to disease
activity and after treatment was initiated no more weight loss was observed (p = 0.0436 in late-
treated rats at day 11 vs. day 4, and p = 0.9009 in late-treated rats at day 22 vs. day 11) (S3 Fig).
Importantly, administration of celastrol has already been tested in healthy animals in a wide
range of concentrations [21]. So far, there are no data showing deleterious effects at a dose of
1mg/kg (the concentration used in this work).
Celastrol diminishes systemic proinflammatory cytokine IL-6 in vivo
Proinflammatory cytokines, namely IL-1β, IL-6, IL-17 and TNF act synergistically to maintain
inflammation and bone erosions in animal models of arthritis and in RA patients. These cyto-
kines activate the NF-kB pathway that in turn leads to the downstream up-regulation of several
cytokines, chemokines and MMPs, which are responsible for the inflammatory process and for
the destruction of cartilage and bone. We therefore aimed at evaluating the anti-inflammatory
effect of celastrol on the peripheral circulating levels of these cytokines. We have observed that
IL-6 levels increase in the serum of AIA rats throughout the course of arthritis, although abun-
dant production was seen only after 2 weeks of disease onset. Thus, IL-6, which is produced by
monocytes/macrophages, T cells and synovial fibroblasts [50], seems to be involved in the sys-
temic events underlying arthritis, especially in the transition phase of its development. Fig 2
shows that celastrol administration significantly reduces the levels of IL-6 detected in periph-
eral blood, both in early and late treatment groups (p<0.0001 in both groups vs. arthritic rats
Fig 2. Celastrol reduces the serum levels of IL-6 in arthritic rats.Notice that celastrol treatment
significantly reduces the systemic concentration of the proinflammatory cytokine IL-6 to levels similar to
healthy controls. Data are expressed as median with interquartile range. Differences were considered
statistically significant for p-values<0.05, according to the Kruskal-Wallis (Dunn´s Multiple Comparison tests)
and Mann–Whitney tests. Healthy N = 21, Arthritic N = 23, Celastrol early group N = 15 and Celastrol late
group N = 15.
doi:10.1371/journal.pone.0142448.g002
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after 22 days of disease induction), presenting a cytokine concentration similar to healthy con-
trols. Importantly, both treated groups showed a significant reduction in the circulating levels
of IL-6 when compared with their baselines (p = 0.0387 in celastrol early-treated vs. arthritic
rats sacrificed at day 4 and p<0.0001 in celastrol-late treated vs. arthritic rats sacrificed at day
11). This observation is corroborated by data already published which shows that IL-6 mRNA
is decreased after celastrol treatment in vitro [51]. We have also quantified the circulating con-
centration of IL-1β, IL-17 and TNF, but no differences were found when comparing arthritic
rats with animals under celastrol treatment or with healthy controls (p>0.05, S4 Fig), possibly
because these cytokines are not increased in the periphery at this stage of disease development.
Previously, we have demonstrated that circulating IL-1β and IL-17 are only increased in the
early phase of RA, in contrast to IL-6, which was found to be increased also in the later phase
of the disease [18], arguing that the detection of these cytokines in the periphery is dependent
on disease evolution. In addition, literature controversy highlights the likelihood that systemic
markers and mediators of arthritis might not fully reflect the underlying local disease progres-
sion. AIA rat model have increased levels of IL-1β (since the preclinical disease stage), IL-6, IL-
17 and TNF (in the acute and chronic stages) locally in the joints [42]. Recently, it has been
shown in the same animal model that both Tripterygium and celastrol decrease the levels of
these cytokines locally in the arthritic joints [19, 20, 22, 52].
Celastrol ameliorates local joint inflammation and bone damage in AIA
rats
To evaluate the effect of celastrol in the preservation of local articular joint synovium and bone
structures, paw sections stained with hematoxylin and eosin were performed (illustrative
images can be observed in Fig 3). The histological evaluation using 4 semi-quantitative scores
is depicted in Fig 4.
The levels of the sublining layer infiltration (Fig 4A) and the lining layer cell numbers (Fig
4B) started to augment immediately after 4 days of disease onset and continued to markedly
increase until the end of the study (p<0.0001, healthy vs. arthritic rats sacrificed after 22 days
of disease induction). The data from Fig 4D revealed that rats treated with celastrol had a nor-
mal joint structure at the end of the study period, with an abrogation of the inflammatory infil-
trate and a reduction of the number of cells present in the lining layer of the synovial
membrane (p<0.0001 in early and late treatment groups vs. arthritic animals). Moreover,
when comparing the infiltration score of celastrol early-treated group with diseased animals at
baseline (day 4), we observed that there was a complete clearance of the cellular infiltrate
(p = 0.0006 in the early-treated group sacrificed at the end of the treatment period vs. arthritic
rats sacrificed at baseline of the treatment period, i.e. after 4 days of disease induction), with a
phenotype similar to a healthy control. Regarding the analysis of the lining layer cell number
score (Fig 4B), data showed that both celastrol early and late treatment groups have dramati-
cally reduced scores, in comparison with the animals at the beginning of treatment, corre-
sponding to baseline (p = 0.0107 in early-treated arthritic rats sacrificed at the end of the study
period vs. arthritic rats sacrificed at baseline, at day 4 and p<0.0001 in late-treated arthritic
rats sacrificed at the end of the study period vs. arthritic rats sacrificed at baseline, at day 11,
respectively).
Celastrol is also effective in preventing bone articular destruction as shown in Fig 4C. The
development of bone erosions in the AIA rat model occurred immediately after 4 days of dis-
ease onset, and markedly increased throughout the development of arthritis (p<0.0001 in
healthy vs. arthritic rats sacrificed after 22 days of disease induction), with a strong correlation
between erosion and infiltration as well as with proliferation scores (r2 = 0.70, p = 0.0009 and
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r2 = 0.97, p<0.0001, respectively). By the end of the treatment course, celastrol was able to sup-
press the appearance of bone erosions (p<0.0001 in both celastrol early and late treatment
groups vs. arthritic rats), maintaining the phenotype similar to their baselines. These results
might suggest that celastrol is able to modulate oscleoclast pathways. In fact, a study has dem-
onstrated that celastrol inhibits the formation and activity of mature osteoclasts, induces their
apoptosis and reduces osteoblast viability and activity in vitro [53].
Overall, these data are supported by studies already published in the literature using several
plant extracts and different experimental outlines [19, 20, 22, 54, 55]. Thus, there is strong
Fig 3. Histological images of joints after celastrol treatment. These patterns are merely illustrative of the
type of histological features observed. Black arrow indicates the absence/presence of ankle swelling in rat
hind paws. C–calcaneus, E–edema or erosion, S–synovia, Tb–tibia, Ts–tarso. Magnification of 50×. Bar:
100 μm.
doi:10.1371/journal.pone.0142448.g003
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evidence that celastrol is able to significantly diminish inflammation and bone damage, even
when administrated in a later phase of arthritis development.
Celastrol inhibits synovial lymphocyte infiltration and cell proliferation in
arthritic rat joints
The immunohistochemical analysis revealed that arthritic rats treated with celastrol have
reduced levels of lymphocyte infiltration into the joints (Fig 5). As can be observed in Fig 5B
there were significant reductions of CD3+ T cells (p<0.0001 in early and late treatment groups
vs. arthritic rats) and CD19+ B cells (p<0.0001 in early and late treatment groups vs. arthritic
rats). In contrast, the number of these cells markedly increased throughout disease progression
in untreated animals (p<0.0001 in healthy vs. arthritic rats, sacrificed at the end of the study
period). A study by Venkatesha et al, have shown that celastrol reduces the level of chemokines,
which might explain the inhibition of leukocyte migration [20].
In addition, we have also studied cell proliferation by staining joint tissue sections with the
Ki67 marker. The immunohistochemical results shown in Fig 5B revealed that animals treated
with celastrol have reduced levels of synovial cell proliferation in both early and late treated rats
(p<0.0001 in both groups vs. arthritic animals), with a score similar to the healthy controls.
Results of immunohistochemical quantification also showed that celastrol significantly
reduced CD3+ T cells (p = 0.0079 in both early and late treatment groups vs. arthritic rats) and
CD19+ B cells (p = 0.0317 in both early and late treatment groups vs. arthritic rats) infiltrated
into the joints as well as synovial cell proliferation (p = 0.0079 in both early and late treatment
groups vs. arthritic rats), as depicted in Fig 5C.
Fig 4. Celastrol suppresses arthritic inflammation and tissue damage locally in the joints of AIA rats.
A semi-quantitative evaluation of histological sections was performed. Notice that celastrol has inhibited
cellular infiltration (A), completely reversed the number of lining layer cells to the normal values (B) and
prevented bone erosion occurrence (C), allowing for a normal joint structure comparable to healthy rats in
both early and late treatment groups (D). Data are expressed as median with interquartile range. Differences
were considered statistically significant for p-values<0.05, according to the Kruskal-Wallis (Dunn´s Multiple
Comparison tests) and Mann–Whitney tests. Correlation analysis was performed using the Spearman test.
Healthy N = 19, Arthritic N = 23, Celastrol early group N = 15 and Celastrol late group N = 15.
doi:10.1371/journal.pone.0142448.g004
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Celastrol significantly reduces CD68+ macrophages in the arthritic
synovial tissue
The activated macrophages in the synovium are derived from circulating monocytes and
secrete various mediators that participate in arthritis induction and tissue injury. Studies of
drug efficacy in RA patients have identified, from a large panel of synovial biomarkers, sublin-
ing CD68+ macrophages as an optimal marker to evaluate clinical response, with an associa-
tion between clinical improvement and the reduction of CD68+ macrophage scores. Therefore,
CD68+ sublining macrophages have been recognized as a synovial biomarker, with a high sen-
sitivity in discriminating between effective and ineffective therapies or placebo, useful in an
early stage of drug development [34, 56]. We have thus performed the characterization of
CD68+ macrophages present in the synovial tissue after treatment with celastrol (Fig 6).
Arthritic rats have shown an increase in the number of CD68+ synovial macrophages through-
out the development of the disease (p<0.0001 in healthy vs. arthritic rats, as shown in Fig 6B).
Importantly, celastrol significantly decreased the number of CD68+ macrophages infiltrated
into the arthritic joint tissue (p<0.0001 in early and late treatment groups vs. arthritic rats). In
addition, celastrol administration significantly decreased the levels of CD163+ macrophages
(p<0.0001 in early and late treatment groups vs. arthritic rats). CD163 is a useful marker in
Fig 5. Celastrol reduces the number of T cells and B cells present in the synovial membrane, and suppresses synovial cell proliferation. (A)
Representation of the immunohistochemical evaluation performed in paw sections at day 22 after celastrol treatment. Magnifications of 200×. Bar: 100 μm.
(B) Immunohistochemical analysis was performed using a semi-quantitative score. Notice that both celastrol early and late-treated rats showed a significant
reduction in the number of CD3 and CD19 positive cells as well as a reduction in the levels of synovial cell proliferation assessed by Ki67 marker in
comparison with arthritic rats at day 22. Healthy N = 16, Arthritic N = 10, Celastrol early group N = 15 and Celastrol late group N = 15. (C)
Immunohistochemical quantification was performed using an image analysis software written in MATLAB to identify and count the number of positive cells for
each antibody in representative sections. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD3, CD19 and
Ki67 positive cells in comparison with arthritic rats at day 22. Healthy N = 5, Arthritic N = 5, Celastrol early group N = 5 and Celastrol late group N = 5. Data are
expressed as median with interquartile range. Differences were considered statistically significant for p-values<0.05, according to the Kruskal-Wallis (Dunn´s
Multiple Comparison tests) and Mann–Whitney tests.
doi:10.1371/journal.pone.0142448.g005
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this context because it is a more selective macrophage marker and helps to discriminate
between synovial macrophages and synovial intimal fibroblasts, which also stain positively for
CD68 in RA synovium [57]. Previous studies have in fact shown that synovial intimal fibro-
blasts migration and invasion into the synovium are also reduced by celastrol [55, 58].
Results of immunohistochemical quantification shown in Fig 6C also revealed that celastrol
significantly reduced CD68+ cells (p = 0.0079 in both early and late treatment groups vs.
arthritic rats) and CD163+ macrophages (p = 0.0079 in both early and late treatment groups
vs. arthritic rats) infiltrated into the joints.
Because inflammatory synovial tissue macrophages are derived from peripheral blood
monocytes, these observations suggest decreased monocyte recruitment into the joints of
arthritic rats treated with celastrol, even when treatment was initiated in a later phase of disease
development.
Discussion
In this study, we have shown that celastrol substantially depletes CD68+ sublining synovial
cells, considered to be the biomarker with the strongest association with response to treatment
in RA. Moreover, celastrol was effective and safe in suppressing synovial inflammation and
bone damage in rats with AIA.
We have consistently observed that celastrol treatment reduced serum IL-6 levels in arthritic
rats. This observation is relevant because IL-6 is a proinflammatory cytokine that plays a rele-
vant role in the pathogenesis of RA, namely in Th17 polarization and plasma B cell differentia-
tion, in the production of chemokines, adhesion molecules, and VEGF, and in the secretion of
RANKL and MMPs, amplifying inflammatory cell infiltration and inducing osteoclastogenesis
[59–61]. Interestingly, it was shown that celastrol can suppress arthritis in part by altering
Th17/Treg ratio in inflamed joints [52]. Additionally, celastrol-treated rats showed a significant
Fig 6. Celastrol reduces the number of synovial CD68+macrophages. (A) Representation of the immunohistochemical evaluation performed in paw
sections at day 22 after celastrol treatment. Magnifications of 200×. Bar: 100 μm. (B) Immunohistochemical analysis was performed using a semi-quantitative
score. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD68 and CD163 positive cells in comparison with
arthritic rats at day 22. Healthy N = 16, Arthritic N = 10, Celastrol early group N = 15 and Celastrol late group N = 15. (C) Immunohistochemical quantification
was performed using an image analysis software written in MATLAB to identify and count the number of positive cells for each antibody in representative
sections. Notice that both celastrol early and late-treated rats showed a significant reduction in the number of CD68 and CD163 positive cells in comparison
with arthritic rats at day 22. Healthy N = 5, Arthritic N = 5, Celastrol early group N = 5 and Celastrol late group N = 5. Data are expressed as median with
interquartile range. Differences were considered statistically significant for p-values<0.05, according to the Kruskal-Wallis (Dunn´s Multiple Comparison
tests) and Mann–Whitney tests.
doi:10.1371/journal.pone.0142448.g006
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reduction in the severity of clinical arthritis as well as in pannus formation and leukocyte cell
infiltration into the joint synovial tissue. This cell infiltration and proliferation inhibitory effect
of celastrol may thus prove to be of interest to prevent and treat the development of the syno-
vial tumor-like pannus tissue characteristic of established RA and responsible for bone damage.
Interestingly, histological analysis also revealed that celastrol is effective in suppressing local
inflammation-induced bone loss. Of note, celastrol treatment is effective when administrated
both in the early and established phase of arthritis, which is relevant for the potential clinical
implications of our findings. Our report is the first to demonstrate the protective coupled effect
of celastrol in vivo on both synovial inflammation and joint bone damage restoring synovial
homeostasis, fulfilling this unmet medical need in RA treatment approach. Importantly, CD68
+ sublining macrophages, a synovial biomarker with a high sensitivity in selecting effective RA
therapies in an early stage of drug development, is significantly reduced in the synovia of celas-
trol-treated rats.
It has already been reported that celastrol targets NF-kB, via long-lasting inhibition of IKKβ
activity [62]. In fact, the inactivation of NF-kB in animal models has shown the ability to sup-
press arthritis [63]. NF-kB participates in the transcription of genes encoding many proinflam-
matory cytokines and chemokines, in the regulation of different immune cells and in the
expression of adhesion molecules and matrix MMPs [64]. Based on microarray gene expres-
sion profile it has been demonstrated that celastrol represses cell proliferation, inflammation
and immune responses (targets T and B cells, antigen processing and presentation), blocks
metabolic pathways, has anti-oxidant properties, and targets VEGF, proinflammatory cyto-
kines and chemokines [65]. Indeed, it has been demonstrated that celastrol reduces the levels
of chemokines, possibly affecting leukocyte migration [20]. Celastrol has thus a broad spectrum
of targets, modulating immune responses rather than inducing immunosuppression [65]. Our
results point out that pure celastrol used in the AIA rat model is not associated with increased
risk of infections, have no hepatotoxicity or nephrotoxicity, suggesting that at least for short-
term RA treatment, celastrol might be a safe drug.
Overall, our results validate celastrol as a promising compound for the treatment of inflam-
mation and inflammation-induced bone damage and provide relevant insights into the usage
of celastrol as a future drug for RA. It would be interesting to extend this knowledge by study-
ing the anti-arthritic properties of celastrol in vivo using different animal models of arthritis,
namely the CIA model, and evaluate differences in efficacy depending on animal gender.
Supporting Information
S1 Fig. Ankle perimeter kinetics. Celastrol was administered to AIA rats both in the early (4
days after disease induction) and late (11 days after disease induction) phases of arthritis devel-
opment. Notice that after 7 days of treatment celastrol early-treated rats presented an ankle
perimeter similar to the healthy control, whereas arthritic rats started to increase left ankle
edema/swelling sharply. In the celastrol late-treated group, ankle swelling started to increase in
parallel to the augment of the inflammatory score, but after treatment was initiated ankle
perimeter started to significantly decrease. Data are expressed as median with interquartile
range. Differences were considered statistically significant for p-values<0.05, according to the
Kruskal-Wallis (Dunn´s Multiple Comparison tests) and Mann–Whitney tests. Healthy
N = 19, Arthritic N = 23, Celastrol early group N = 15 and Celastrol late group N = 15.
(TIF)
S2 Fig. Administration of pure celastrol induces no hepatic or renal toxicity. At day 22 after
disease induction no hepatocellular or renal lesion was observed in any of the animals. Liver
and kidney samples from all animals were analyzed by a pathologist blinded to experimental
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groups but only representative histological sections are shown. H&E staining; Magnifications
of 100×. Bar: 300 μm.
(TIF)
S3 Fig. Celastrol treatment has no effect on body weight.Notice that no weight loss was
observed due to celastrol administration. In contrast, there was an association between disease
activity and weight loss, which was highlighted in late-treated rats that started to lose weight
due to disease activity (day 4 up to day 11) and after treatment was initiated no more weight
loss was observed (day 11 up to day 22). Data are expressed as median with interquartile range.
Differences were considered statistically significant for p-values<0.05, according to the Mann–
Whitney tests.
(TIF)
S4 Fig. Celastrol has no effect in the serum levels of IL-1β, IL-17 and TNF in arthritic rats.
Data are expressed as median with interquartile range. Differences were considered statistically
significant for p-values<0.05, according to the Kruskal-Wallis (Dunn´s Multiple Comparison
tests) and Mann–Whitney tests. Healthy N = 19, Arthritic N = 23, Celastrol early group N = 15
and Celastrol late group N = 15.
(TIF)
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